Mustang Bio Establishes Car T Cell Therapy Manufacturing Facility in Massachusetts

Mustang Bio Establishes Car T Cell Therapy Manufacturing Facility in Massachusetts

Mustang Bio, Inc. , a Fortress Biotech, Inc. company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell technology, announced today that it has entered into a lease agreement with the UMass Medicine Science Park in Worcester, Massachusetts, for a manufacturing facility to support the clinical development and commercialization of the Company's CAR T product candidates. The facility is expected to be operational for the production of personalized CAR T therapies in 2018.

from Biotech News